Camptothecin Attenuates Cytochrome P450 3A4 Induction by Blocking the Activation of Human Pregnane X Receptor
- 26 May 2010
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in The Journal of pharmacology and experimental therapeutics
- Vol. 334 (3), 999-1008
- https://doi.org/10.1124/jpet.110.168294
Abstract
Differential regulation of drug-metabolizing enzymes (DMEs) is a common cause of adverse drug effects in cancer therapy. Due to the extremely important role of cytochrome P450 3A4 (CYP3A4) in drug metabolism and the dominant regulation of human pregnane X receptor (hPXR) on CYP3A4, finding inhibitors for hPXR could provide a unique tool to control drug efficacies in cancer therapy. Camptothecin (CPT) was demonstrated as a novel and potent inhibitor (IC50 = 0.58 μM) of an hPXR-mediated transcriptional regulation on CYP3A4 in this study. In contrast, one of its analogs, irinotecan (CPT-11), was found to be an hPXR agonist in the same tests. CPT disrupted the interaction of hPXR with steroid receptor coactivator-1 but had effects on neither the competition of ligand binding nor the formation of the hPXR and retinoid X receptor α heterodimer, nor the interaction between the regulatory complex and DNA-responsive elements. CPT treatment resulted in delayed metabolism of nifedipine in human hepatocytes treated with rifampicin, suggesting a potential prevention of drug-drug interactions between CYP3A4 inducers and CYP3A4-metabolized drugs. Because CPT is the leading compound of topoisomerase I inhibitors, which comprise a quickly developing class of anticancer agents, the findings indicate the potential of a new class of compounds to modify hPXR activity as agonists/inhibitors and are important in the development of CPT analogs.Keywords
This publication has 48 references indexed in Scilit:
- A Human Immunodeficiency Virus Protease Inhibitor Is a Novel Functional Inhibitor of Human Pregnane X ReceptorDrug Metabolism and Disposition, 2007
- The far and distal enhancers in the CYP3A4 gene co-ordinate the proximal promoter in responding similarly to the pregnane X receptor but differentially to hepatocyte nuclear factor-4αBiochemical Journal, 2007
- Human Pregnane X Receptor Antagonists and Agonists Define Molecular Requirements for Different Binding SitesMolecular Pharmacology, 2007
- Crystal structure of the PXR–T1317 complex provides a scaffold to examine the potential for receptor antagonismBioorganic & Medicinal Chemistry, 2007
- Relative Activation of Human Pregnane X Receptor versus Constitutive Androstane Receptor Defines Distinct Classes of CYP2B6 and CYP3A4 InducersJournal of Pharmacology and Experimental Therapeutics, 2006
- Retinoid X Receptor-α-Dependent Transactivation by a Naturally Occurring Structural Variant of Human Constitutive Androstane Receptor (NR1I3)Molecular Pharmacology, 2005
- Increased Hepatobiliary Clearance of Unconjugated Thyroxine Determines DMP 904-Induced Alterations in Thyroid Hormone Homeostasis in RatsToxicological Sciences, 2005
- Role of Cytochrome P450 Activity in the Fate of Anticancer Agents and in Drug ResistanceClinical Pharmacokinetics, 2005
- Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cellsInternational Journal of Cancer, 2004
- Nuclear Receptor Response Elements Mediate Induction of Intestinal MDR1 by RifampinPublished by Elsevier BV ,2001